139 related articles for article (PubMed ID: 28743532)
1. A synthetic peptide hijacks the catalytic subunit of class I PI3K to suppress the growth of cancer cells.
Guo W; You X; Wang X; Wang L; Chen Y
Cancer Lett; 2017 Oct; 405():1-9. PubMed ID: 28743532
[TBL] [Abstract][Full Text] [Related]
2. PAQR3 modulates insulin signaling by shunting phosphoinositide 3-kinase p110α to the Golgi apparatus.
Wang X; Wang L; Zhu L; Pan Y; Xiao F; Liu W; Wang Z; Guo F; Liu Y; Thomas WG; Chen Y
Diabetes; 2013 Feb; 62(2):444-56. PubMed ID: 23086038
[TBL] [Abstract][Full Text] [Related]
3. Molecular Mechanisms of Human Disease Mediated by Oncogenic and Primary Immunodeficiency Mutations in Class IA Phosphoinositide 3-Kinases.
Dornan GL; Burke JE
Front Immunol; 2018; 9():575. PubMed ID: 29616047
[TBL] [Abstract][Full Text] [Related]
4. Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.
Sun M; Hillmann P; Hofmann BT; Hart JR; Vogt PK
Proc Natl Acad Sci U S A; 2010 Aug; 107(35):15547-52. PubMed ID: 20713702
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of PI3K p110α contributes to acquired resistance to MET inhibitor, in MET-amplified SNU-5 gastric xenografts.
Ji F; Liu X; Wu Y; Fang X; Huang G
Drug Des Devel Ther; 2015; 9():5697-704. PubMed ID: 26543351
[TBL] [Abstract][Full Text] [Related]
6. Effects of tyroserleutide on gene expression of calmodulin and PI3K in hepatocellular carcinoma.
Zhao L; Zhao Q; Lu R; Fu Z; Zhu Z; Jia J; Wang S; Shi L; Jian X; Yao Z
J Cell Biochem; 2008 Feb; 103(2):471-8. PubMed ID: 17546603
[TBL] [Abstract][Full Text] [Related]
7. The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells.
Zhao JJ; Liu Z; Wang L; Shin E; Loda MF; Roberts TM
Proc Natl Acad Sci U S A; 2005 Dec; 102(51):18443-8. PubMed ID: 16339315
[TBL] [Abstract][Full Text] [Related]
8. Class IA phosphoinositide 3-kinases are obligate p85-p110 heterodimers.
Geering B; Cutillas PR; Nock G; Gharbi SI; Vanhaesebroeck B
Proc Natl Acad Sci U S A; 2007 May; 104(19):7809-14. PubMed ID: 17470792
[TBL] [Abstract][Full Text] [Related]
9. Structural basis for activation and inhibition of class I phosphoinositide 3-kinases.
Vadas O; Burke JE; Zhang X; Berndt A; Williams RL
Sci Signal; 2011 Oct; 4(195):re2. PubMed ID: 22009150
[TBL] [Abstract][Full Text] [Related]
10. Direct positive regulation of PTEN by the p85 subunit of phosphatidylinositol 3-kinase.
Chagpar RB; Links PH; Pastor MC; Furber LA; Hawrysh AD; Chamberlain MD; Anderson DH
Proc Natl Acad Sci U S A; 2010 Mar; 107(12):5471-6. PubMed ID: 20212113
[TBL] [Abstract][Full Text] [Related]
11. C-Type Lectin-Like Receptor 2 Suppresses AKT Signaling and Invasive Activities of Gastric Cancer Cells by Blocking Expression of Phosphoinositide 3-Kinase Subunits.
Wang L; Yin J; Wang X; Shao M; Duan F; Wu W; Peng P; Jin J; Tang Y; Ruan Y; Sun Y; Gu J
Gastroenterology; 2016 May; 150(5):1183-1195.e16. PubMed ID: 26855187
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of p85, the non-catalytic subunit of phosphatidylinositol 3-kinase, exerts potent antitumor activity in human breast cancer cells.
Folgiero V; Di Carlo SE; Bon G; Spugnini EP; Di Benedetto A; Germoni S; Pia Gentileschi M; Accardo A; Milella M; Morelli G; Bossi G; Mottolese M; Falcioni R
Cell Death Dis; 2012 Dec; 3(12):e440. PubMed ID: 23222510
[TBL] [Abstract][Full Text] [Related]
13. Regulation of the p85/p110 phosphatidylinositol 3'-kinase: stabilization and inhibition of the p110alpha catalytic subunit by the p85 regulatory subunit.
Yu J; Zhang Y; McIlroy J; Rordorf-Nikolic T; Orr GA; Backer JM
Mol Cell Biol; 1998 Mar; 18(3):1379-87. PubMed ID: 9488453
[TBL] [Abstract][Full Text] [Related]
14. Differential enhancement of breast cancer cell motility and metastasis by helical and kinase domain mutations of class IA phosphoinositide 3-kinase.
Pang H; Flinn R; Patsialou A; Wyckoff J; Roussos ET; Wu H; Pozzuto M; Goswami S; Condeelis JS; Bresnick AR; Segall JE; Backer JM
Cancer Res; 2009 Dec; 69(23):8868-76. PubMed ID: 19903845
[TBL] [Abstract][Full Text] [Related]
15. The negative regulation of phosphoinositide 3-kinase signaling by p85 and it's implication in cancer.
Luo J; Cantley LC
Cell Cycle; 2005 Oct; 4(10):1309-12. PubMed ID: 16131837
[TBL] [Abstract][Full Text] [Related]
16. Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (pI3K): differential interactions with the regulatory subunit p85 and with RAS.
Zhao L; Vogt PK
Cell Cycle; 2010 Feb; 9(3):596-600. PubMed ID: 20009532
[TBL] [Abstract][Full Text] [Related]
17. Interaction of the retinal insulin receptor beta-subunit with the p85 subunit of phosphoinositide 3-kinase.
Rajala RV; McClellan ME; Chan MD; Tsiokas L; Anderson RE
Biochemistry; 2004 May; 43(19):5637-50. PubMed ID: 15134438
[TBL] [Abstract][Full Text] [Related]
18. Class I PI3K in oncogenic cellular transformation.
Zhao L; Vogt PK
Oncogene; 2008 Sep; 27(41):5486-96. PubMed ID: 18794883
[TBL] [Abstract][Full Text] [Related]
19. Class IA PI3K regulatory subunits: p110-independent roles and structures.
Fox M; Mott HR; Owen D
Biochem Soc Trans; 2020 Aug; 48(4):1397-1417. PubMed ID: 32677674
[TBL] [Abstract][Full Text] [Related]
20. The inhibition of p85αPI3KSer83 phosphorylation prevents cell proliferation and invasion in prostate cancer cells.
Feola A; Cimini A; Migliucci F; Iorio R; Zuchegna C; Rothenberger R; Cito L; Porcellini A; Unteregger G; Tombolini V; Giordano A; Di Domenico M
J Cell Biochem; 2013 Sep; 114(9):2114-9. PubMed ID: 23553770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
